EGFR and ovarian carcinoma: Interestingly, we showed that GPR30 and ERα, together with the EGFR/MAPK pathway, are involved in the biological response to atrazine in ovarian cancer cells, which is in accordance with our recent investigation showing that the selective GPR30 ligand G-1 exerts biological activity similar to that of atrazine without binding or activating ERα (Albanito et al. 2007).